Phase 1 Study of Oral RH324 in Advanced Non-Small Cell Lung Cancer

Description

Phase 1 open label dose ranging study of RH324 in advanced non-small cell lung cancer

Conditions

Safety Issues

Study Overview

Study Details

Study overview

Phase 1 open label dose ranging study of RH324 in advanced non-small cell lung cancer

A Phase 1 Open Label Dose Ranging Study of Oral RH324 in Advanced Non-Small Cell Lung Cancer

Phase 1 Study of Oral RH324 in Advanced Non-Small Cell Lung Cancer

Condition
Safety Issues
Intervention / Treatment

-

Contacts and Locations

Cleveland

Case Comprehensive Cancer Center University Hospitals, Cleveland, Ohio, United States, 44106

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Advanced Non-Small Cell Lung Cancer
  • * Measurable Target Lesion by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
  • * Failed all standard of care including chemotherapy, targeted therapy, and immunotherapy
  • * Adults over 18 years
  • * Performance status (Eastern Cooperative Oncology Group) less than or equal to 2
  • * Life expectancy greater than 2 months
  • * Laboratory Values:
  • * No history of hyperthyroidism
  • * Abstinence from alcohol and supplements
  • * Not pregnant, lactating and willing to use birth control throughout study
  • * Able to provide consent
  • * Positive Emission Tomography/Computer Tomography part of subjects care plan at baseline
  • * Prior use of Withania somnifera
  • * Phenylketonuria
  • * Inability to swallow capsules
  • * Hypersensitivity to study drug ingredients
  • * Unstable medical or surgical condition
  • * History of additional cardiac risk factors
  • * Requiring drugs that are "strong" inhibitors of cytochrome P450
  • * Requiring irradiation
  • * Requiring intravenous fluids or hyperalimentation
  • * Requiring transfusions, dialysis, or other procedures
  • * Active infection
  • * Human Immunodeficiency Virus
  • * Must exceed washout period of prior treatments
  • * Psychiatric, neurological or other reason that precludes subjects ability to participate

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

ReHeva Biosciences,Inc.,

Study Record Dates

2025-01-01